
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay is well-positioned for future growth with its groundbreaking Deep TMS platform technology, which has shown impressive remission and response rates in treating mental health disorders. The recent FDA approval for the at-home use of the ProlivRx system shows strong potential for expanded market access and reimbursement, while the accelerated SWIFT protocol offers a significantly faster and more convenient treatment option for patients. With a strong financial position and a promising market outlook, BrainsWay is expected to continue driving adoption and making a positive impact in the field of interventional psychiatry.
Bears say
BrainsWay is a medtech firm with solid operating performance and a positive medium- to long-term outlook, indicated by its recent full-year financial results and the expected growth in revenue for the next two years. However, the company's stock may face challenges due to the recent change in the ratio of American Depositary Shares to ordinary shares, which has resulted in a decreased 12-month price target of $15 from $30 per share. Additionally, there are certain risks to consider, such as slow uptake of their products, difficulty in expanding reimbursement and market access, and potential dilution risk.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares